FATE THERAPEUTICS INC

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

25 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

01 Oct 2021 08:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

15 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

02 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

19 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

04 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

04 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

02 Aug 2021 16:50:19 By Nasdaq GlobeNewswire

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

16 Jul 2021 08:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

15 Jul 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

15 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting

04 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

25 May 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

13 May 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress

05 May 2021 16:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results

29 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting

27 Apr 2021 16:31:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service

25 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

08 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress

24 Feb 2021 16:01:00 By Nasdaq GlobeNewswire